Interferon alpha-2b in the long-term treatment of essential thrombocythemia

S. Sacchi, A. Tabilio, P. Leoni, A. Riccardi, A. Vecchi, C. Messora, F. Falzetti, S. Rupoli, G. Ucci, M. F. Martelli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We treated 35 patients affected with essential thrombocythemia (ET) with interferon (IFN) alpha-2b. Our treatment scheme consisted of (a) a 6-month induction phase and (b) a continuous maintenance phase. During the induction phase, our results showed that using 21 million units (mu) of IFN weekly platelet counts fell below 600×109/l in about 90% of patients. These data demonstrate that well-tolerated doses of IFN can rapidly correct excessive thrombocytosis. During the continuous maintenance phase, 61% of patients required 3 mu three times a week, 15% once a week, and 24% daily. Thus the minimal IFN doses able to maintain platelet count below 600×109/l varied between 3 and 21 mu per week. During long-term treatment, subjective side effects were tolerable, especially using 3 mu three times a week. We conclude that IFN alpha-2b is an effective drug in the long-term treatment of ET.

Original languageEnglish
Pages (from-to)206-209
Number of pages4
JournalAnnals of Hematology
Volume63
Issue number4
DOIs
Publication statusPublished - Oct 1991

Fingerprint

interferon alfa-2b
Essential Thrombocythemia
Interferons
Platelet Count
Maintenance
Thrombocytosis
Therapeutics
Pharmaceutical Preparations

Keywords

  • Essential thrombocythemia
  • Interferon alpha
  • Long-term treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Sacchi, S., Tabilio, A., Leoni, P., Riccardi, A., Vecchi, A., Messora, C., ... Martelli, M. F. (1991). Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Annals of Hematology, 63(4), 206-209. https://doi.org/10.1007/BF01703444

Interferon alpha-2b in the long-term treatment of essential thrombocythemia. / Sacchi, S.; Tabilio, A.; Leoni, P.; Riccardi, A.; Vecchi, A.; Messora, C.; Falzetti, F.; Rupoli, S.; Ucci, G.; Martelli, M. F.

In: Annals of Hematology, Vol. 63, No. 4, 10.1991, p. 206-209.

Research output: Contribution to journalArticle

Sacchi, S, Tabilio, A, Leoni, P, Riccardi, A, Vecchi, A, Messora, C, Falzetti, F, Rupoli, S, Ucci, G & Martelli, MF 1991, 'Interferon alpha-2b in the long-term treatment of essential thrombocythemia', Annals of Hematology, vol. 63, no. 4, pp. 206-209. https://doi.org/10.1007/BF01703444
Sacchi, S. ; Tabilio, A. ; Leoni, P. ; Riccardi, A. ; Vecchi, A. ; Messora, C. ; Falzetti, F. ; Rupoli, S. ; Ucci, G. ; Martelli, M. F. / Interferon alpha-2b in the long-term treatment of essential thrombocythemia. In: Annals of Hematology. 1991 ; Vol. 63, No. 4. pp. 206-209.
@article{b491636e5c7d4a41afb60125e640d981,
title = "Interferon alpha-2b in the long-term treatment of essential thrombocythemia",
abstract = "We treated 35 patients affected with essential thrombocythemia (ET) with interferon (IFN) alpha-2b. Our treatment scheme consisted of (a) a 6-month induction phase and (b) a continuous maintenance phase. During the induction phase, our results showed that using 21 million units (mu) of IFN weekly platelet counts fell below 600×109/l in about 90{\%} of patients. These data demonstrate that well-tolerated doses of IFN can rapidly correct excessive thrombocytosis. During the continuous maintenance phase, 61{\%} of patients required 3 mu three times a week, 15{\%} once a week, and 24{\%} daily. Thus the minimal IFN doses able to maintain platelet count below 600×109/l varied between 3 and 21 mu per week. During long-term treatment, subjective side effects were tolerable, especially using 3 mu three times a week. We conclude that IFN alpha-2b is an effective drug in the long-term treatment of ET.",
keywords = "Essential thrombocythemia, Interferon alpha, Long-term treatment",
author = "S. Sacchi and A. Tabilio and P. Leoni and A. Riccardi and A. Vecchi and C. Messora and F. Falzetti and S. Rupoli and G. Ucci and Martelli, {M. F.}",
year = "1991",
month = "10",
doi = "10.1007/BF01703444",
language = "English",
volume = "63",
pages = "206--209",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Interferon alpha-2b in the long-term treatment of essential thrombocythemia

AU - Sacchi, S.

AU - Tabilio, A.

AU - Leoni, P.

AU - Riccardi, A.

AU - Vecchi, A.

AU - Messora, C.

AU - Falzetti, F.

AU - Rupoli, S.

AU - Ucci, G.

AU - Martelli, M. F.

PY - 1991/10

Y1 - 1991/10

N2 - We treated 35 patients affected with essential thrombocythemia (ET) with interferon (IFN) alpha-2b. Our treatment scheme consisted of (a) a 6-month induction phase and (b) a continuous maintenance phase. During the induction phase, our results showed that using 21 million units (mu) of IFN weekly platelet counts fell below 600×109/l in about 90% of patients. These data demonstrate that well-tolerated doses of IFN can rapidly correct excessive thrombocytosis. During the continuous maintenance phase, 61% of patients required 3 mu three times a week, 15% once a week, and 24% daily. Thus the minimal IFN doses able to maintain platelet count below 600×109/l varied between 3 and 21 mu per week. During long-term treatment, subjective side effects were tolerable, especially using 3 mu three times a week. We conclude that IFN alpha-2b is an effective drug in the long-term treatment of ET.

AB - We treated 35 patients affected with essential thrombocythemia (ET) with interferon (IFN) alpha-2b. Our treatment scheme consisted of (a) a 6-month induction phase and (b) a continuous maintenance phase. During the induction phase, our results showed that using 21 million units (mu) of IFN weekly platelet counts fell below 600×109/l in about 90% of patients. These data demonstrate that well-tolerated doses of IFN can rapidly correct excessive thrombocytosis. During the continuous maintenance phase, 61% of patients required 3 mu three times a week, 15% once a week, and 24% daily. Thus the minimal IFN doses able to maintain platelet count below 600×109/l varied between 3 and 21 mu per week. During long-term treatment, subjective side effects were tolerable, especially using 3 mu three times a week. We conclude that IFN alpha-2b is an effective drug in the long-term treatment of ET.

KW - Essential thrombocythemia

KW - Interferon alpha

KW - Long-term treatment

UR - http://www.scopus.com/inward/record.url?scp=0025940284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025940284&partnerID=8YFLogxK

U2 - 10.1007/BF01703444

DO - 10.1007/BF01703444

M3 - Article

C2 - 1932299

AN - SCOPUS:0025940284

VL - 63

SP - 206

EP - 209

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -